Bicara Therapeutics Inc. Stock Split Ratio
Bicara Therapeutics Inc. (BCAX) reported Stock Split Ratio of 10.82% for the 1-month period ending 2024-09-30, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Equity
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2026-03-30
- 2024-09-30: Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month 10.82%.
- 2022-01-31: Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month 42.80%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month |
|---|---|
| 2024-09-30 | 10.82% 10-K · filed 2026-03-30 |
| 2022-01-31 | 42.80% 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |